Clin Epidemiol:入院前口服二磷酸盐增加卒中患者30天死亡率?

2015-09-10 MedSci MedSci原创

目的:应用二磷酸盐增加卒中死亡率的风险。研究人员调查入院前口服二磷酸盐与卒中住院患者30天死亡率的关系。方法:研究人员进行了一项全国范围内人群队列研究,选取2004年7月1号到2012年12月31号期间丹麦医疗数据库中首次因卒中住院的100043名患者。应用Cox回归计算校正HR值作为30天死亡率与当前应用二磷酸盐(卒中前90天内应用)或者最近应用二磷酸盐(卒中前90-180天内应用)相关的RR值

目的:应用二磷酸盐增加卒中死亡率的风险。研究人员调查入院前口服二磷酸盐与卒中住院患者30天死亡率的关系。 


方法:研究人员进行了一项全国范围内人群队列研究,选取2004年7月1号到2012年12月31号期间丹麦医疗数据库中首次因卒中住院的100043名患者。应用Cox回归计算校正HR值作为30天死亡率与当前应用二磷酸盐(卒中前90天内应用)或者最近应用二磷酸盐(卒中前90-180天内应用)相关的RR值。当前应用又分为新近应用或者长期应用。

结果:
急性缺血性卒中患者(AIS)51982名,脑内出血患者(ICH)11789名,蛛网膜下腔出血患者(SAH)4528名,31754名患者卒中类型不明。与未用二磷酸盐患者相比,当前应用药物的AIS (11.9% vs 8.5% )ICH (43.2% vs 34.5% )SAH(40.3% vs 23.2%)患者的30天死亡风险增加。然而,校正分析后,当前应用二磷酸盐不能增加AIS(MRR, 0.87; 95%CI: 0.75, 1.01) ICH(MRR, 1.05; 95% CI: 0.90, 1.23) SAH(MRR, 1.15; 95% CI: 0.83, 1.61)以及不明类型卒中患者30天死亡率(MRR, 0.94; 95% CI: 0.81, 1.09)。也就是说,死亡率与当前用药没有相关性。对用药类型进行校正分析,发现新用磷酸二钠药(MRR, 1.40; 95% CI: 1.01, 1.93)增加卒中患者死亡率,而当前应用阿仑磷酸钠(MRR, 0.87; 95% CI: 0.74, 1.02)可降低AIS患者死亡率。

结论:没有证据证明入院前应用二磷酸盐药物增加卒中患者30天死亡率。

原文出处:

Christensen DH, Horváth-Puhó E, Schmidt M,et al. The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients. Clin Epidemiol. 2015 Aug 24;7:381-9. eCollection. 2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977755, encodeId=1d9719e775598, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Apr 28 09:54:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769935, encodeId=acbe1e6993501, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Sun Dec 27 00:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720055, encodeId=201f1e20055a3, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 07 08:54:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024510, encodeId=86ea2024510ef, content=<a href='/topic/show?id=606523999e4' target=_blank style='color:#2F92EE;'>#二磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23999, encryptionId=606523999e4, topicName=二磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Dec 01 20:54:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459907, encodeId=15ce145990e03, content=<a href='/topic/show?id=e50ce3859fe' target=_blank style='color:#2F92EE;'>#磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73859, encryptionId=e50ce3859fe, topicName=磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ea6208793, createdName=chenshujs, createdTime=Sat Sep 12 00:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=)]
    2016-04-28 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977755, encodeId=1d9719e775598, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Apr 28 09:54:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769935, encodeId=acbe1e6993501, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Sun Dec 27 00:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720055, encodeId=201f1e20055a3, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 07 08:54:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024510, encodeId=86ea2024510ef, content=<a href='/topic/show?id=606523999e4' target=_blank style='color:#2F92EE;'>#二磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23999, encryptionId=606523999e4, topicName=二磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Dec 01 20:54:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459907, encodeId=15ce145990e03, content=<a href='/topic/show?id=e50ce3859fe' target=_blank style='color:#2F92EE;'>#磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73859, encryptionId=e50ce3859fe, topicName=磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ea6208793, createdName=chenshujs, createdTime=Sat Sep 12 00:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977755, encodeId=1d9719e775598, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Apr 28 09:54:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769935, encodeId=acbe1e6993501, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Sun Dec 27 00:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720055, encodeId=201f1e20055a3, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 07 08:54:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024510, encodeId=86ea2024510ef, content=<a href='/topic/show?id=606523999e4' target=_blank style='color:#2F92EE;'>#二磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23999, encryptionId=606523999e4, topicName=二磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Dec 01 20:54:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459907, encodeId=15ce145990e03, content=<a href='/topic/show?id=e50ce3859fe' target=_blank style='color:#2F92EE;'>#磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73859, encryptionId=e50ce3859fe, topicName=磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ea6208793, createdName=chenshujs, createdTime=Sat Sep 12 00:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977755, encodeId=1d9719e775598, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Apr 28 09:54:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769935, encodeId=acbe1e6993501, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Sun Dec 27 00:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720055, encodeId=201f1e20055a3, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 07 08:54:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024510, encodeId=86ea2024510ef, content=<a href='/topic/show?id=606523999e4' target=_blank style='color:#2F92EE;'>#二磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23999, encryptionId=606523999e4, topicName=二磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Dec 01 20:54:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459907, encodeId=15ce145990e03, content=<a href='/topic/show?id=e50ce3859fe' target=_blank style='color:#2F92EE;'>#磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73859, encryptionId=e50ce3859fe, topicName=磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ea6208793, createdName=chenshujs, createdTime=Sat Sep 12 00:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977755, encodeId=1d9719e775598, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Apr 28 09:54:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769935, encodeId=acbe1e6993501, content=<a href='/topic/show?id=51469830949' target=_blank style='color:#2F92EE;'>#院前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98309, encryptionId=51469830949, topicName=院前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ca38130612, createdName=mhzhuang@stu.e, createdTime=Sun Dec 27 00:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720055, encodeId=201f1e20055a3, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 07 08:54:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024510, encodeId=86ea2024510ef, content=<a href='/topic/show?id=606523999e4' target=_blank style='color:#2F92EE;'>#二磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23999, encryptionId=606523999e4, topicName=二磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Dec 01 20:54:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459907, encodeId=15ce145990e03, content=<a href='/topic/show?id=e50ce3859fe' target=_blank style='color:#2F92EE;'>#磷酸盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73859, encryptionId=e50ce3859fe, topicName=磷酸盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ea6208793, createdName=chenshujs, createdTime=Sat Sep 12 00:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=)]

相关资讯

Stroke:机械通气的卒中患者再入院率增高?

气管切开术是严重缺血性卒中,脑出血,蛛网膜下腔出血患者常用的处理方式。但是对行机械通气的卒中患者的再入院率的了解较少。我们按照国际疾病分类法,第九版临床修订准则,收集3个州的非联邦急诊护理医院所有的出院患者的数据。我们比较行机械通气的卒中患者的再入院率,这些卒中患者分为行气管切开术和未行气管切开术两类。在39881名在卒中住院期间行机械通气,并且存活到出院的患者,10690名(26.8%, 95%

J Stroke Cerebrovasc Dis:他汀类药物能够降低LDL-C急性卒中患者的死亡率

为了调查住院患者他汀类药物治疗对低密度脂蛋白胆固醇(LDL-C<1.81 mmol/L)水平的急性卒中患者死亡率的影响。从中国国家登记表中招募急性卒中患者,患者LDL-C低于1.81 mmol/L。住院期间根据患者是否应用他汀类治疗,将患者分为他汀组和非他汀组。应用多变量二元logistic回归模型分析患者进行他汀类药物治疗和患者1年死亡率之间的关系。招募了1018名患者,3个月累积死亡率为

J Neurol Neurosur Ps:工作日入院的卒中患者有更好的预后

背景:医疗环境中存在着“周末”效应,但是对卒中患者的影响尚不清楚。目的:调查卒中入院时间对患者处理过程以及卒中预后的影响。方法:应用苏格兰数据库(2005-2013)中的数据,入院时间分为工作日,周日晚上以及周末/公共节假日。主要的处理措施为入院当天的吞咽功能筛查,脑扫描(0或1天),应用阿司匹林(0或1天),入住卒中病房(0或1天),溶栓治疗(0或1天)。校正病例混杂因素后,应用多变量logis

Stroke:血清瘦素能降低卒中发生风险?

背景和目的:血清瘦素是调节体重平衡和能量代谢的主要脂肪素。血清瘦素水平与卒中发生风险的关系认识尚不一致。我们主要是为了验证血清瘦素水平与老年人卒中发生的风险相关这一假说。方法:对非卒中受试者757人血清瘦素水平进行检测,受试者(平均年龄79岁,62%女性)是第22个检验周期(1990-1994)中的Framingham研究组中的成员。确定受试者所有脑卒中以及缺血性卒中的发生。结果:平均随访时间10

J Cardiol:尿石症患者增加心血管事件的发生

背景:尽管许多证据表明尿石症患者增加心血管疾病(CVD)的发生,但是尿石症与CVD事件发生的关系的纵向性研究较少。研究人员调查台湾人群队列数据库中,患有尿石症患者和心肌梗塞(MI)或卒中发生的相关性。方法:研究人员在台湾国家健康保险研究数据库随机抽取100万人的信息进行分析。81536名年龄在18岁及以上患者,在研究期间40773名患者诊断为尿石症,选取相匹配的40773名无尿石症的患者作为对照。

Stroke:卒中患者配偶的长期健康生活质量下降?

研究者普遍研究卒中患者对家庭短期的影响。这篇研究主要想评估卒中患者配偶长期的健康相关生活质量。在萨尔格学院缺血性卒中研究中收集卒中患者,对照组和配偶7年随访的相关数据。应用SF-36评估配偶健康相关生活质量,用NIHSS,简易精神状态量表,抑郁量表,焦虑量表,BI以及mRS评估卒中患者的状况。招募248对卒中患者,初发卒中小于70岁,245对为对照组。卒中患者配偶和对照组配偶的年龄的中位数分别为6